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Type II diabetes (T2D)3 represents a major public
health challenge, with the WHO having estimated a
current prevalence of 346 million worldwide. Cardio-
vascular disease, including coronary heart disease
(CHD), stroke, and peripheral vascular disease, is one
of the major complications of T2D, and the develop-
ment of new strategies to tackle this problem is un-
doubtedly necessary. Although the association between
diabetes and cardiovascular risk is well established, the
pathologic basis of CHD in patients with T2D may dif-
fer from that in the general population. Whether this
relationship has a genetic component is not fully
understood.
With regard to understanding the genetic basis of
complex diseases, genomewide association studies
(GWASs) have led to an unprecedented number of
well-validated variants associated with complex dis-
eases. There is now considerable interest in under-
standing both the mechanism by which these variants
confer risk and whether the variants identified will be
useful for predicting complex disease phenotypes.
A recent report by Qi et al. (1 ) addressed 2 ques-
tions in this regard: (a) Are single-nucleotide polymor-
phisms (SNPs) identified by GWASs of CHD associ-
ated with the risk of CHD in T2D, and (b) can these
variants be combined in a score that will aid prediction
of CHD risk in T2D? In investigating these questions,
Qi and coworkers genotyped 12 CHD susceptibility
loci in 3 nested case– control studies of CHD in T2D:
the Nurses’ Health Study, the Health Professional
Follow-Up Study, and the Joslin Heart Study.
As expected, the chromosome 9p21 CHD risk lo-
cus showed a strong association with CHD risk,
whereas 4 other loci [PHACTR14 (phosphatase and ac-
tin regulator 1), HNF1A (HNF1 homeobox A), PCSK9
(proprotein convertase subtilisin/kexin type 9), and
SORT1 (sortilin 1)] demonstrated associations consis-
tent with those seen in previous GWAS reports, with
P values 0.05. Interestingly, haplotypes associated
with increased CHD risk and defined by SNPs in the
gene cluster containing the SLC22A3 [solute carrier
family 22 (extraneuronal monoamine transporter),
member 3], LPAL2 [lipoprotein, Lp(a)-like 2, pseudo-
gene], and LPA [lipoprotein, Lp(a)] genes did not ap-
pear significantly associated with CHD risk, possibly
because of the variants’ low frequencies and the inade-
quate statistical power of the studies. None of the other
variants tested showed associations with CHD below
the significance threshold (P  0.05), although the au-
thors noted that 2 of the loci examined [MRAS (muscle
RAS oncogene homolog) and KCNE2 (potassium
voltage-gated channel, Isk-related family, member 2)]
had summary effect sizes in the direction opposite to
that described in previous reports. Although it may be
tempting to speculate on the reasons for this result, the
95% CI for the summary odds ratios crosses the line of
null effect, and the study had limited power to detect
overall effects. Therefore, these results should be inter-
preted with caution.
The authors then constructed a simple un-
weighted genetic risk score (GRS) based on the number
of risk alleles carried (each individual will carry 0, 1, or
2 risk alleles at each locus) and assessed the perfor-
mance of the GRS in predicting CHD. In common with
other reports of studies that used a similar methodol-
ogy, the discriminative performance of the GRS was
modest (area under the ROC curve, 0.5782). Addition
of the GRS to a panel of clinical risk factors did lead to
a modest improvement in both the area under the ROC
curve and the net reclassification index. Two important
features that could have aided in discrimination but
were not included in the clinical parameters are the
duration of diabetes in patients who developed CHD
and the age of diabetes diagnosis.
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Some aspects of the study design may limit the
overall interpretation of the results, particularly in re-
lation to the potential for translation to clinical care.
First, the clinical predictors included in the regres-
sion model (age, sex, hemoglobin A1c, HDL choles-
terol, and a history of smoking, hypertension, and hy-
percholesterolemia) were not based on a score that is in
common clinical use, such as the Framingham Risk
Score algorithm, so comparison with standard prac-
tices was not possible.
Second, 2 of the SNPs included in the risk score (in
the SORT1 and PCSK9 genes) are associated with cir-
culating lipid concentrations, which were included
among the clinical predictors. That may have led to
overfitting of the model.
Third, the authors point to the fact that partici-
pants with 8 risk alleles have an almost doubling of
the risk for CHD events. Although this effect may seem
relatively large, there are some caveats to consider. This
odds ratio compared the highest risk group with the
lowest risk group, not with the mean risk group. When
the score was considered as a continuous predictor, the
effect was considerably smaller (odds ratio, 1.19). Al-
though identifying those at the extremes of genetic risk
may seem an attractive strategy, doing so by definition
will have an impact on the number needed to screen to
prevent 1 event, because the number of people at the
extremes is small (2 ). Furthermore, with regard to pri-
mary prevention of CHD, it is likely that measures that
target the entire diabetic population will be of the
greatest benefit, because the largest absolute number of
events will occur in people with intermediate risk, as
proposed by Rose’s prevention paradox (3 ).
Finally, the selection of SNPs included in the
model warrants consideration. If genetic variants are to
be used in clinical practice to predict the development
of disease phenotypes, a robust method will be needed
to identify the specific variants to be included in such
risk profiles. Although all 12 loci examined in this study
have previously shown a reproducible association with
CHD risk in the general population, only SNPs that
were associated with CHD in the cohorts tested were
included in the score. To objectively answer the ques-
tion, do GWAS CHD SNPs predict CHD in T2D? re-
quires that all of the variants be tested in combination,
because the current study does not have power to rule
out an effect in patients with diabetes. Furthermore,
calculating the P value used as a threshold for inclusion
of SNPs in the score should have accounted for multi-
ple testing; doing so would have led to only 2 SNPs
showing “significant” associations.
What makes this study noteworthy is the fact that
the authors used a meaningful genetic risk-prediction
study, because it was conducted in a high-risk popula-
tion group that might benefit from targeting novel pre-
ventive interventions. Indeed, the GRS has the poten-
tial to benefit younger individuals with T2D who have
not yet developed cardiovascular risk factors, which
would identify susceptibility for the disease or its sever-
ity. Although that may be a theoretical benefit when
discussing personalized-medicine models, there are
many factors to consider. We have previously shown
that the use of T2D risk alleles in a GRS to predict T2D
did not add anything to validated T2D risk algorithms
(4 ). Interestingly, many of the interventions that are
currently used in primary prevention are directed at
these same risk factors, some of which may not have yet
become apparent, such as increased blood pressure and
dyslipidemia. Therefore, other than aiding in advising
on a healthy lifestyle, it is hard to see exactly how the
test will guide physicians.
This study can be added to those that have shown
moderately disappointing results with respect to using
genetic tests to predict complex disease, but it can help
guide future efforts in this regard. Understanding the
genetic architecture of CHD in T2D is necessary, how-
ever, and although this study does make some progress
in that regard, much larger studies are required to
begin to address many of the unanswered questions.
An additional caveat needs consideration. The Women’s
Health Initiative study, which has reported on
1 004 466 person-years of follow-up, found a con-
cerning increase in new cases of T2D in postmeno-
pausal women on statins, even after adjustment for con-
founders (5). Although the relationship between statins
and T2D has been examined previously in metaanalyses
(with variable outcomes), this relationship needs careful
consideration. The pandemic of obesity will lead to in-
creasing numbers of children and adolescents diagnosed
with T2D. Given the well-established link between T2D
and premature cardiovascular deaths, the need for effi-
cient early predictive tools and aggressive preventive in-
terventions becomes more urgent.
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